Adult stem cells replenish dying cells and regenerate damaged tissues throughout our lifetime. We lose many of those stem cells, along with their regenerative capacity, as we age. Working in flies and mice, researchers at the Buck Institute and elsewhere discovered that TOR, a nutrient sensing pathway which is central to the aging process, drives the loss of adult stem cells. Treating mice with the TOR-inhibitor rapamycin prevented this loss and could reverse age-related loss of stem cells in mouse trachea. The research is published in Cell Stem Cell.
In most of our tissues, adult stem cells hang out in a quiet state - ready to be activated in case of infection or injury. In response to such injury, however, stem cells have to be able to rapidly divide, to generate daughter cells that differentiate into cells that repair the tissue. This division has to be "asymmetric", meaning that only one of the two cells generated during the stem cell division goes on to differentiate, while the other cell remains a stem cell.
Buck professor and senior author Heinrich Jasper, PhD, says previous research showed that TOR needs to be maintained at a low level in order to preserve stem cells in a quiet state and prevent their differentiation. But in this study, researchers discovered that TOR signaling becomes activated in many stem cell types when they are engaged in a regenerative response. Jasper, who is now a staff scientist at Genentech, says this activation is important for rapid tissue repair, but at the same time it also increases the probability that stem cells will differentiate, thus losing their stem cell status. Jasper says this loss - in this case in the fly intestine, mouse muscle and mouse trachea - is particularly prevalent when the tissue is under heavy or chronic pressure to regenerate, which occurs in response to infections or other trauma to the tissue. During aging, Jasper says that repeated or chronic activation of TOR signaling contributes to the gradual loss of stem cells. Accordingly, by performing genetic or pharmacological interventions to limit TOR activity chronically, the researchers were able to prevent or reverse stem cell loss in tracheae and muscle of aging mice.
"It's all about maintaining a balance between stem cell renewal and differentiation," said Jasper. "It's easy to see how a loss of adult stem cells might accrue over a lifetime and accelerate with aging. We are excited to have a means of rescuing stem cells, boosting their ability to maintain healthy tissue."
The work at the Buck Institute, led by postdoctoral fellow Samantha Haller, PhD, began in the intestines of fruit flies and moved to mouse trachea - tissues that share many similarities. Experiments involving mouse muscle were done at Stanford University. At the Buck Institute, mice were put on differing regimens of rapamycin treatment starting at different stages of life. Jasper says rapamycin was able to rescue stem cells even when given to mice starting at 15 months of age - the human equivalent of 50 years of age. "In every case we saw a decline in the number of stem cells, and rapamycin would bring it back." Whether this recovery of tissue stem cell numbers is due to a replenishment of the stem cell pool from more differentiated cells, or due to an increase in "asymmetric" stem cell divisions that allow one stem cell to generate two new ones, remains to be answered, he said.
Jasper says TOR can be regulated by a number of stimuli, and researchers are now attempting to better understand how the activity of this signaling pathway is controlled in stem cells. "Is there a chronic increase in TOR over a lifetime, or is activation stronger in aging animals? What happens downstream of TOR?" Jasper says researchers at the Buck are also testing homologues of rapamycin that are more specifically aimed at TOR Complex 1 - a key complex containing TOR that regulates cell growth and metabolism in all complex organisms.
Citation: mTORC1 activation during repeated regeneration impairs somatic stem cell maintenance
Other Buck researchers involved in the study include Samantha Haller, Subir Kapuria, Rebeccah R. Riley, Monique N. O'Leary, Katherine H. Schreiber, Julie K. Andersen, Simon Melov and Brian Kennedy. Other collaborators include Thomas A. Rando and Joseph T. Rodgers, Paul Glenn Laboratories for the Biology of Aging, Stanford University, Stanford, CA; Jianwen Que, Department of Medicine, Columbia University, New York, NY; and Jason Rock, Department of Anatomy, USCF School of Medicine, San Francisco, CA.
The work was supported by grants from the National Institutes of Health R01 AG041764, R01 AG047497, R01 DK100342.
About the Buck Institute for Research on Aging
The Buck Institute is the U.S.'s first independent research organization devoted to Geroscience - focused on the connection between normal aging and chronic disease. Based in Novato, California, the Buck is dedicated to extending "healthspan," the healthy years of human life, and does so by utilizing a unique interdisciplinary approach involving laboratories studying the mechanisms of aging and others focused on specific diseases. Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer's and Parkinson's, cancer, cardiovascular disease, macular degeneration, osteoporosis, diabetes and stroke. In their collaborative research, they are supported by the most recent developments in genomics, proteomics, bioinformatics and stem cell technologies. For more information: http://www.